PTEN and breast carcinoma: Given the low number of patients with HR+/HER2+ breast cancers in both PTEN cohorts, we further assessed HR negativity and HER2 positivity, as solo, along with PTEN status (Fig. 4b, c and Supplementary Fig. S2b, c).